FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos, +11

British Journal of Cancer

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

G. Stathopoulos, K. Syrigos, Gerasimos Aravantinos, +10

British Journal of Cancer

UrologyPancreatic CancerGemcitabine MonotherapyGastrointestinal OncologyMedicine +13

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

D. Mavroudis, Emmanouil Saloustros, N. Malamos, +5

Annals of Oncology

Breast OncologyOncologyDose-dense ChemotherapyBreast CancerAdjuvant Trastuzumab +4

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A E Athanasiou, Nikolaos Ziras, +6

Lung Cancer

Liposomal CisplatinMedicinePathologyPhase Ii StudyAnti-cancer Agent +5

Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial

D. Pectasides, John Glotsos, N Bountouroglou, +5

Annals of Oncology

UrologyPhase Ii TrialGenitourinary CancerMedicineWeekly Chemotherapy +2

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

G. Stathopoulos, K. Syrigos, Aristidis Polyzos, +10

Annals of Oncology

Surgical OncologyPancreatic CancerGastrointestinal OncologyMedicinePhase Ii Study +6

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, +21

Annals of Oncology

High-risk Stage IiOncologyGastrointestinal OncologyCancer ManagementAdjuvant Chemotherapy +7

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Dimitriοs Mavroudis, Pavlos Papakotoulas, Alexandros Ardavanis, +9

Annals of Oncology

Advanced Breast CancerBreast OncologyOncologyMedicinePhase Iii Trial +6

<i>KRAS</i>,<i>NRAS</i>and<i>BRAF</i>mutations in Greek and Romanian patients with colorectal cancer: a cohort study

Șerban Negru, Eirini Papadopoulou, Angela Apessos, +12

BMJ Open

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

Aristides Polyzos, Nikolaos Malamos, Ioannis Boukovinas, +14

Breast Cancer Research and Treatment

Breast OncologyOncologyRandomized StudyCancer ManagementAdjuvant Chemotherapy +6